Literature DB >> 11341927

Phosphodiester and phosphorothioate oligonucleotide condensation and preparation of antisense nanoparticles.

M Junghans1, J Kreuter, A Zimmer.   

Abstract

Protamine is a cationic peptide with a molecular mass of approx. 4000 Da that is able to condense DNA. In the present study it was used to complex antisense oligonucleotides (ODNs) and to form solid particles with initial diameters of 90-150 nm. The reaction was very rapid and occurred by simple mixing of diluted solutions of the polycation with the oligonucleotide. The aggregation was dependent on the oligonucleotide chain length and the protamine/ODN mass ratio. Particle formation required a minimal chain length of nine nucleotides and a mass ratio of 0.5:1. The particle surface charge and the number of particles depended on the mass ratio. With increasing amounts of the peptide, the number of particles and the zeta potential increased. Both negatively and positively charged particles improved the stability of oligonucleotides against DNase I digestion. Above a mass ratio of 2.5:1 no degradation was found. The uptake of unbound rhodamine-labelled ODNs and its complexes with protamine was determined with Vero cells under in vitro cell culture conditions at 37 degrees C and 4 degrees C. At 37 degrees C the cellular uptake increased with increasing mass ratio. The internalized oligonucleotides were localized in the cytoplasm and in the nucleus of the cells. When Vero cells were treated with these samples at 4 degrees C for 4 h, no fluorescence could be detected inside the cells. Therefore, our data indicate an energy dependent endocytotic uptake mechanism. In contrast, spermine and spermidine, which are also known condensation agents, did not aggregate with oligonucleotides into nanoparticles under the same conditions.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11341927     DOI: 10.1016/s0167-4838(00)00219-3

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

Review 2.  Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.

Authors:  Elias Fattal; Gillian Barratt
Journal:  Br J Pharmacol       Date:  2009-04-02       Impact factor: 8.739

3.  Constitutive expression Of NGF And P75(NTR) affected by bladder distension and NGF antisense treatment.

Authors:  Mahendra Kashyap; Subrata Pore; Naoki Yoshimura; Pradeep Tyagi
Journal:  Life Sci       Date:  2016-02-05       Impact factor: 5.037

4.  Enhanced cellular uptake of a triplex-forming oligonucleotide by nanoparticle formation in the presence of polypropylenimine dendrimers.

Authors:  Latha M Santhakumaran; Thresia Thomas; T J Thomas
Journal:  Nucleic Acids Res       Date:  2004-04-15       Impact factor: 16.971

5.  Accelerated stem cell labeling with ferucarbotran and protamine.

Authors:  Daniel M Golovko; Tobias Henning; Jan S Bauer; Marcus Settles; Thomas Frenzel; Artur Mayerhofer; Ernst J Rummeny; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2009-09-12       Impact factor: 5.315

Review 6.  Use of Protamine in Nanopharmaceuticals-A Review.

Authors:  Ivana Ruseska; Katja Fresacher; Christina Petschacher; Andreas Zimmer
Journal:  Nanomaterials (Basel)       Date:  2021-06-07       Impact factor: 5.076

7.  Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.

Authors:  Gyati Shilakari Asthana; Abhay Asthana; Dharm Veer Kohli; Suresh Prasad Vyas
Journal:  Biomed Res Int       Date:  2014-06-26       Impact factor: 3.411

8.  Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration.

Authors:  Bernhard Scheicher; Cornelia Lorenzer; Katrin Gegenbauer; Julia Partlic; Fritz Andreae; Alexander H Kirsch; Alexander R Rosenkranz; Oliver Werzer; Andreas Zimmer
Journal:  PLoS One       Date:  2016-11-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.